Brown-Forman Rejects $15 Billion Takeover Bid from Sazerac
The rejection follows Brown-Forman ending merger talks with the French spirits maker Pernod Ricard late last month.
Already have an account? Sign in.
The rejection follows Brown-Forman ending merger talks with the French spirits maker Pernod Ricard late last month.
Evommune reported EVO756 failed to meet its primary endpoint in the Phase 2b CSU trial. The company is discontinuing development in urticaria but advancing the drug in atopic dermatitis with data expected in Q3 2026.
The acquisition adds over 2 billion tons of limestone reserves and creates $85M in annual synergies.
Positive long-term data for Larimar’s nomlabofusp in Friedreich’s ataxia: 100% frataxin response and walking recovery signals. FDA accelerated pathway opens, but safety issues weigh on stock.